Manulife Financial (MFC) Earnings Date & Reports

Key Takeaways

• Core earnings per share (EPS) rose 16% year-over-year to C$1.09, narrowly beating the analyst consensus estimate of C$1.08, according to LSEG data.
• Net income attributed to shareholders reached C$2.1 billion, up 17% from C$1.79 billion in the same quarter last year.
• Asia segment core earnings surged 21% (in U.S. dollars), while the U.S. segment posted a 55% jump in core earnings, offsetting a 10% decline in Canada.
• Annual Premium Equivalent (APE) sales — a key measure of new insurance business — climbed 21%, with all three insurance segments delivering double-digit top-line growth.
• Manulife announced a C$3.2 billion long-term care (LTC) reinsurance transaction with Munich Re, marking the third such deal in under three years to reduce balance-sheet risk.
• Global Wealth and Asset Management (Global WAM) net inflows slowed to C$0.4 billion from C$0.9 billion a year earlier, though gross flows rose 33% to C$58.7 billion.

Earnings Context and Why It Matters

Manulife Financial Corporation's second quarter 2026 results carried added weight after the company missed Wall Street expectations in the first quarter. Investors were closely watching whether the Toronto-based insurer could regain momentum and capitalize on what industry observers describe as the most favorable environment for life insurers in over a decade, supported by normalized bond yields and stabilized mortality trends. Manulife has spent the past decade pivoting its growth strategy toward Asia, targeting half of its core earnings from the region by 2027, making each quarterly update a key checkpoint on that strategic journey. With the stock trading near all-time highs heading into the release, the bar for execution was elevated.

Reported Results

Manulife reported core earnings of C$1.923 billion for the second quarter ended June 30, 2026, a 12% increase on a constant exchange rate (CER) basis compared with C$1.726 billion in the prior-year period. Core EPS came in at C$1.09, up 16% year-over-year and one cent above the LSEG consensus of C$1.08. On a GAAP (Generally Accepted Accounting Principles) basis, net income attributed to shareholders reached C$2.110 billion, or C$1.20 per share, representing a 22% increase from the C$0.98 reported in the second quarter of 2025.

Core return on equity (ROE) — a measure of profitability relative to shareholder capital — expanded to 16.3%, up 130 basis points from 15.0% a year earlier, while reported ROE reached 18.0%. The company's LICAT ratio (Life Insurance Capital Adequacy Test), a key regulatory capital metric for Canadian insurers, stood at 136%, well above the supervisory target and reflecting a fortified balance sheet.

On the top line, APE sales — which combine regular premium payments and a portion of single-premium products into an annualized measure — grew 21% to C$2.698 billion. New business CSM (Contractual Service Margin), representing the expected future profit from newly issued insurance contracts, rose 16% to C$1.024 billion. New business value (NBV), another gauge of the profitability of new sales, increased 10% to C$929 million.

Segment performance revealed a tale of geographic divergence. Asia continued to be the standout, with core earnings climbing 21% to US$616 million and APE sales up 21%, driven by strong demand across Hong Kong and other Asian markets. The U.S. segment delivered a 55% surge in core earnings to US$218 million, helped by fewer claims in both life insurance and LTC policies. Canada was the lone soft spot, with core earnings declining 10% to C$379 million, weighed down by higher expenses in group insurance. Global WAM posted a 9% increase in core earnings to C$505 million, with its core EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin expanding 110 basis points to 31.2%. However, net inflows of C$0.4 billion marked a deceleration from C$0.9 billion in the prior-year quarter.

Separately, the company announced a C$3.2 billion reinsurance agreement with Munich Re covering a standalone block of LTC policies — the third such risk-transfer transaction in less than three years. Under the deal, Manulife will reinsure 80% of the biometric risk with no asset transfer, retaining a future earnings stream as the portfolio matures.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool allows traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-powered signals. Whether scanning for breakout candidates, trending names, or stocks exhibiting specific fundamental profiles, the AI Screener streamlines the discovery process and surfaces trade ideas more efficiently than manual screening. Explore the AI Screener to see how data-driven filtering can sharpen your market research.

Market Reaction and Investor Sentiment

Manulife's shares closed at C$62.44 on the Toronto Stock Exchange on August 5, down 0.86% on the day of the earnings release. The modest decline likely reflects the mixed nature of the report: while core EPS edged past consensus and Asia delivered robust growth, the slowdown in Global WAM net inflows and the softness in Canada may have tempered enthusiasm. Broader sentiment around the stock remains constructive, with the company reaching a new 52-week high of C$63.02 in the trading session immediately before the report. Analyst consensus remains at "Buy," with several firms recently raising price targets to the C$69–C$70 range. CEO Phil Witherington emphasized the company's disciplined execution and accelerating AI integration, while CFO Colin Simpson highlighted the 20% year-over-year increase in the CSM balance as evidence of strengthened future earnings capacity.

Forward Outlook and Key Factors to Monitor

Looking ahead, Manulife's trajectory will be shaped by several interconnected factors. The Asia growth engine remains central to the investment thesis, and investors should monitor whether the region can sustain its 20%-plus core earnings growth as Manulife pushes toward its 2027 target of deriving half of core earnings from Asia. The company's ability to maintain positive net flows in Global WAM will also be closely watched, particularly given the deceleration observed in the second quarter.

The LTC reinsurance transaction with Munich Re represents a significant step in de-risking the balance sheet. Management characterized this as the third such deal in under three years and the first involving a standalone LTC portfolio. Continued progress on legacy risk reduction could support valuation multiples over time.

On the capital allocation front, Manulife returned C$2.6 billion to shareholders through dividends and share buybacks in the first half of 2026. The financial leverage ratio improved to 22.2% from 23.6% a year earlier, remaining comfortably below the company's 25% medium-term target. The combination of a strong LICAT ratio and disciplined leverage provides flexibility for further capital returns or strategic investments.

Additionally, management's emphasis on AI integration across underwriting, claims processing, and customer experience — with a stated ambition to deliver over C$1 billion of enterprise value by 2027 — introduces a potential efficiency tailwind. The expense efficiency ratio improved to 44.5% in the quarter, suggesting early progress on operational leverage. Investors should track whether these efficiency gains translate into sustained margin expansion across segments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations